<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967199</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2013-01</org_study_id>
    <nct_id>NCT01967199</nct_id>
  </id_info>
  <brief_title>Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Treatment of Drug-Eluting Stent REstenosis Using Drug-Eluting STents vs. Drug-COated Balloon for Preventing REcurrent In-Stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety and effectiveness of paclitaxel eluting
      balloon (SeQuent Please) compared to coronary stenting with the Everolimus-eluting balloon
      expandable stent (Xience Prime or Xience Xpedition or Xience Alpine) in the treatment of drug
      eluting stent restenosis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">April 18, 2013</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late luminal loss</measure>
    <time_frame>9months</time_frame>
    <description>Late luminal loss at 9 months angiographic follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment or in-stent restenosis at 9 month angiographic follow-up</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>3day</time_frame>
    <description>defined as achievement of a final diameter stenosis of &lt;30% by QCA(Quantitative Coronary Angiography) using any percutaneous method, without the occurrence of death, Q wave Myocardial Infarction, or repeat revascularization of the target lesion during the hospital stay.
participants will be followed for the duration of hospital stay, an expected average of 3days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Drug Eluting Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel eluting balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel eluting balloon (SeQuent Please)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting balloon expandable stent</intervention_name>
    <description>Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)</description>
    <arm_group_label>Drug Eluting Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel eluting balloon</intervention_name>
    <description>paclitaxel eluting balloon (SeQuent Please)</description>
    <arm_group_label>paclitaxel eluting balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must be more than or equal to 20 years of age

          -  Restenosis after drug-eluting stents (&gt;50% by visual estimate)

          -  Any Lesion length including focal in stent restenosis or diffuse in stent restenosis

          -  The patient or guardian agrees to the study protocol and the schedule of clinical and
             angiographic follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          -  The patient has a known hypersensitivity or contraindication to any of the following
             medications:

               -  Heparin

               -  Aspirin

               -  Both Clopidogrel and TIclopidine

               -  Sirolimus eluting stent

               -  Stainless steel and/or

               -  Contrast media (patients with documented sensitivity to contrast which can be
                  effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be
                  enrolled. Patients with true anaphylaxis to prior contrast media, however, should
                  not be enrolled)

          -  Systemic (intravenous) Everolimus use within 12 months.

          -  Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrollment into this study

          -  Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may
             result in protocol non-compliance (per site investigator's medical judgment)

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chungjoo</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Service Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A Medical Center</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>M.D, Ph.D.</investigator_title>
  </responsible_party>
  <keyword>drug-eluting stent</keyword>
  <keyword>drug-coated Balloon</keyword>
  <keyword>recurrent In-Stent restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

